

Hans Gelderblom

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2045892/publications.pdf>

Version: 2024-02-01

602
papers

32,861
citations

4146

87
h-index

6131

159
g-index

612
all docs

612
docs citations

612
times ranked

29761
citing authors

#	ARTICLE	IF	CITATIONS
1	Gastrointestinal stromal tumours: ESMOâ€“EURACANâ€“GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2022, 33, 20-33.	1.2	213
2	Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. <i>Clinical Cancer Research</i> , 2022, 28, 1672-1679.	7.0	18
3	SELNET clinical practice guidelines for soft tissue sarcoma and GIST. <i>Cancer Treatment Reviews</i> , 2022, 102, 102312.	7.7	29
4	UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients. <i>European Journal of Cancer</i> , 2022, 162, 148-157.	2.8	27
5	Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment. <i>Clinical Cancer Research</i> , 2022, 28, 1402-1411.	7.0	24
6	Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform. <i>Lancet Oncology</i> , The, 2022, 23, 198-201.	10.7	14
7	Systemic treatment in advanced phyllodes tumor of the breast: a multi-institutional European retrospective case-series analyses. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 603-610.	2.5	4
8	Symptoms reported by gastrointestinal stromal tumour (GIST) patients on imatinib treatment: combining questionnaire and forum data. <i>Supportive Care in Cancer</i> , 2022, 30, 5137-5146.	2.2	3
9	Disease progression in osteosarcoma: a multistate model for the EURAMOS-1 (European and American) Tj ETQq1 1,0,784314 rgBT /O	1.9	1
10	Prognostic Significance of Bone Metastasis in Soft Tissue Sarcoma Patients Receiving Palliative Systemic Therapy: An Explorative, Retrospective Pooled Analysis of the EORTC-Soft Tissue and Bone Sarcoma Group (STBSG) Database. <i>Sarcoma</i> , 2022, 2022, 1-13.	1.3	1
11	The role of perioperative chemotherapy in primary high-grade extremity soft tissue sarcoma: a risk-stratified analysis using PERSARC. <i>European Journal of Cancer</i> , 2022, 165, 71-80.	2.8	8
12	The Stroma Liquid Biopsy Panel Contains a Stromal-Epithelial Gene Signature Ratio That Is Associated with the Histologic Tumor-Stroma Ratio and Predicts Survival in Colon Cancer. <i>Cancers</i> , 2022, 14, 163.	3.7	4
13	Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 62-68.	4.7	32
14	Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approaches. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 333-345.	3.4	7
15	High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 2307-2320.	1.6	24
16	Critical impact of radiotherapy protocol compliance and quality in the treatment of retroperitoneal sarcomas: Results from the EORTC 62092â€“2092 STRASS trial. <i>Cancer</i> , 2022, 128, 2796-2805.	4.1	14
17	Comparable effectiveness of 45- and 20-min post-infusion scalp cooling time in preventing paclitaxel-induced alopecia â€” a randomized controlled trial. <i>Supportive Care in Cancer</i> , 2022, , .	2.2	1
18	A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor. <i>BMC Cancer</i> , 2022, 22, 511.	2.6	6

#	ARTICLE	IF	CITATIONS
19	First-line chemotherapy in advanced intra-abdominal well-differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis. <i>Cancer</i> , 2022, 128, 2932-2938.	4.1	3
20	Short-term and long-term prognostic value of histological response and intensified chemotherapy in osteosarcoma: a retrospective reanalysis of the BOO6 trial. <i>BMJ Open</i> , 2022, 12, e052941.	1.9	1
21	Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 90, 97-104.	2.3	2
22	Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic <i>NTRK</i> fusion-positive (<i>NTRK</i> -fp) solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3099-3099.	1.6	16
23	Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial). <i>BMC Cancer</i> , 2022, 22, .	2.6	6
24	A randomized, placebo-controlled, phase 2 trial of INBRX-109 in unresectable or metastatic conventional chondrosarcoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS11582-TPS11582.	1.6	3
25	Systemic treatment of advanced clear cell sarcoma: results from a retrospective international series from the World Sarcoma Network. <i>ESMO Open</i> , 2022, 7, 100522.	4.5	11
26	Malignant Transformation of Giant Cell Tumor of Bone and the Association with Denosumab Treatment: A Radiology and Pathology Perspective. <i>Sarcoma</i> , 2022, 2022, 1-12.	1.3	2
27	Automated gathering of real-world data from online patient forums can complement pharmacovigilance for rare cancers. <i>Scientific Reports</i> , 2022, 12, .	3.3	2
28	Surgical management of 144 diffuse-type TGCT patients in a single institution: A 20-year cohort study. <i>Journal of Surgical Oncology</i> , 2022, 126, 1087-1095.	1.7	9
29	Value of adjuvant radiotherapy in patients with localized Ewing sarcoma at the extremities: Report from the Ewing 2008 trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 11531-11531.	1.6	0
30	Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer. <i>European Journal of Cancer</i> , 2022, 171, 114-123.	2.8	5
31	Phase III assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: An international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES).. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA2-LBA2.	1.6	11
32	Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study. <i>Annals of Oncology</i> , 2022, 33, 1071-1082.	1.2	36
33	MOTION: A randomized, phase 3, placebo-controlled, double-blind study of vimseltinib (DCC-3014) for the treatment of tenosynovial giant cell tumor.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS11590-TPS11590.	1.6	3
34	Updated concepts in treatment of giant cell tumor of bone. <i>Current Opinion in Oncology</i> , 2022, 34, 371-378.	2.4	14
35	Response to letter entitled re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients. <i>European Journal of Cancer</i> , 2022, 172, 231-233.	2.8	0
36	Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations. <i>Oncologist</i> , 2021, 26, e1347-e1358.	3.7	28

#	ARTICLE	IF	CITATIONS
37	Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing. <i>Clinical Pharmacokinetics</i> , 2021, 60, 89-102.	3.5	6
38	Individualized Dosing of Fluoropyrimidine-Based Chemotherapy to Prevent Severe Fluoropyrimidine-Related Toxicity: What Are the Options?. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 591-604.	4.7	37
39	Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 480-492.	2.0	8
40	Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 143-152.	4.1	15
41	Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013-14) trial. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 741-758.	2.5	27
42	Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors. <i>Oncologist</i> , 2021, 26, e863-e873.	3.7	28
43	Long-term outcomes of pexidartinib in tenosynovial giant cell tumors. <i>Cancer</i> , 2021, 127, 884-893.	4.1	29
44	Prospective practice survey of management of cetuximab-related skin reactions. <i>Supportive Care in Cancer</i> , 2021, 29, 3497-3506.	2.2	1
45	COVID-19 and systemic anticancer therapy: exploiting uncertainty. <i>Lancet Oncology</i> , The, 2021, 22, 3-5.	10.7	2
46	Survival Analysis of 3 Different Age Groups and Prognostic Factors among 402 Patients with Skeletal High-Grade Osteosarcoma. Real World Data from a Single Tertiary Sarcoma Center. <i>Cancers</i> , 2021, 13, 486.	3.7	12
47	The variant T allele of PvuII in ESR1 gene is a prognostic marker in early breast cancer survival. <i>Scientific Reports</i> , 2021, 11, 3249.	3.3	5
48	No need for H2-antagonists in premedication regimens for paclitaxel infusions: less is more. <i>British Journal of Cancer</i> , 2021, 124, 1613-1614.	6.4	3
49	Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature. <i>Cancer Medicine</i> , 2021, 10, 2645-2659.	2.8	23
50	The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 191.	2.7	25
51	Personalising sarcoma care using quantitative multimodality imaging for response assessment. <i>Clinical Radiology</i> , 2021, 76, 313.e1-313.e13.	1.1	7
52	Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)-I. <i>Annals of Oncology</i> , 2021, 32, 533-541.	1.2	34
53	Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spatalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 3620-3629.	7.0	151
54	Nationwide evaluation of mutation-tailored treatment of gastrointestinal stromal tumors in daily clinical practice. <i>Gastric Cancer</i> , 2021, 24, 990-1002.	5.3	6

#	ARTICLE	IF	CITATIONS
55	Treatment Strategies for Metastatic Soft Tissue Sarcomas. <i>Cancers</i> , 2021, 13, 1722.	3.7	5
56	Management of tenosynovial giant cell tumour of the foot and ankle. <i>Bone and Joint Journal</i> , 2021, 103-B, 788-794.	4.4	10
57	Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. <i>Cancer</i> , 2021, 127, 2934-2942.	4.1	96
58	Association of treatment delays with an unfavorable outcome in patients with localized Ewing sarcoma: A retrospective analysis of data from the GPOH Euro-E.W.I.N.G.99 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11502-11502.	1.6	3
59	Intra-patient dose escalation (IPDE) of ripretinib after disease progression in patients with advanced gastrointestinal stromal tumor (GIST): Analyses from the phase 3 INVICTUS study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11536-11536.	1.6	0
60	Retrospective world-wide registry on the efficacy of immune checkpoint inhibitors in alveolar soft part sarcoma: Updated results from sixty patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11564-11564.	1.6	4
61	Critical impact of radiotherapy protocol compliance and quality in the treatment of retroperitoneal sarcomas: Results from the 62092-22092 STRASS trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11566-11566.	1.6	5
62	National survey on access to new oncology drugs pending health technology assessment and financial arrangements.. <i>Journal of Clinical Oncology</i> , 2021, 39, e13599-e13599.	1.6	0
63	Safety and pharmacokinetic analysis of UGT1A1 genotype-guided dosing of irinotecan.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3574-3574.	1.6	3
64	Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2021, 92, 493-499.	3.3	13
65	Phase I trial to determine safety and immunogenicity of amplivant, a synthetic toll-like receptor 2 ligand, conjugated to two HPV16 E6 synthetic long peptides.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2614-2614.	1.6	3
66	Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. <i>ESMO Open</i> , 2021, 6, 100170.	4.5	65
67	Abstract CT123: Population pharmacokinetics of ripretinib in patients with advanced malignancies. <i>Cancer Research</i> , 2021, 81, CT123-CT123.	0.9	1
68	Soft tissue and visceral sarcomas: ESMOâ€œEURACANâ€œGENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-upâ€œ†. <i>Annals of Oncology</i> , 2021, 32, 1348-1365.	1.2	381
69	Patterns of Perioperative Treatment and Survival of Localized, Resected, Intermediate- or High-Grade Soft Tissue Sarcoma: A 2000â€œ2017 Netherlands Cancer Registry Database Analysis. <i>Sarcoma</i> , 2021, 2021, 1-8.	1.3	5
70	Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG â€œANITAâ€œ. <i>European Journal of Cancer</i> , 2021, 152, 26-40.	2.8	10
71	Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2173-2181.	1.0	2
72	Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the <sc>INVICTUS</sc> Study. <i>Oncologist</i> , 2021, 26, e2053-e2060.	3.7	19

#	ARTICLE	IF	CITATIONS
73	Limited evolution of the actionable metastatic cancer genome under therapeutic pressure. <i>Nature Medicine</i> , 2021, 27, 1553-1563.	30.7	41
74	Ripretinib inpatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. <i>European Journal of Cancer</i> , 2021, 155, 236-244.	2.8	19
75	Exposure-response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1422-1432.	2.5	7
76	Comprehensive Molecular Analysis of Inflammatory Myofibroblastic Tumors Reveals Diverse Genomic Landscape and Potential Predictive Markers for Response to Crizotinib. <i>Clinical Cancer Research</i> , 2021, 27, 6737-6748.	7.0	12
77	1540P Ripretinib as 4th-line treatment in patients with advanced gastrointestinal stromal tumor: Long-term update from the phase III INVICTUS study. <i>Annals of Oncology</i> , 2021, 32, S1120-S1121.	1.2	7
78	1541P Real-world data from patients with gastrointestinal stromal tumors (GIST) treated in Dutch GIST expertise centers. <i>Annals of Oncology</i> , 2021, 32, S1121.	1.2	0
79	Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sarcomas. <i>European Journal of Cancer</i> , 2021, 154, 253-268.	2.8	8
80	Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types. <i>Clinical Cancer Research</i> , 2021, 27, 6106-6114.	7.0	9
81	Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous <i>KIT</i> / <i>PDGFRA</i> Mutations in the Phase III INVICTUS Study. <i>Clinical Cancer Research</i> , 2021, 27, 6333-6342.	7.0	25
82	1821P Safety and preliminary efficacy of vimseltinib in tenosynovial giant cell tumor (TGCT). <i>Annals of Oncology</i> , 2021, 32, S1233-S1234.	1.2	5
83	A phase II study on the neo-adjuvant combination of pazopanib and radiotherapy in patients with high-risk, localized soft tissue sarcoma. <i>Acta Oncologica</i> , 2021, 60, 1557-1564.	1.8	5
84	Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021, 32, 1520-1536.	1.2	150
85	Priorities and preferences of advanced soft tissue sarcoma patients starting palliative chemotherapy: baseline results from the HOLISTIC study. <i>ESMO Open</i> , 2021, 6, 100258.	4.5	7
86	The impact of a 1-hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure. <i>International Journal of Cancer</i> , 2021, 148, 2799-2806.	5.1	8
87	Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse. <i>Scientific Reports</i> , 2021, 11, 415.	3.3	10
88	Introducing Fluorescence-Guided Surgery for Pediatric Ewing, Osteo-, and Rhabdomyosarcomas: A Literature Review. <i>Biomedicines</i> , 2021, 9, 1388.	3.2	14
89	Nationwide evaluation of mutation-tailored anti-EGFR therapy selection in patients with colorectal cancer in daily clinical practice. <i>Journal of Clinical Pathology</i> , 2021, , jclinpath-2021-207865.	2.0	0
90	Combined Assessment of the Tumor Stroma Ratio and Tumor Immune Cell Infiltrate for Immune Checkpoint Inhibitor Therapy Response Prediction in Colon Cancer. <i>Cells</i> , 2021, 10, 2935.	4.1	12

#	ARTICLE	IF	CITATIONS
91	Early response evaluation using 18F-FDG-PET/CT does not influence management of patients with metastatic gastrointestinal stromal tumors (GIST) treated with palliative intent. Nuklearmedizin - NuclearMedicine, 2021, 60, 411-416.	0.7	1
92	Intra-Tumoral Pharmacokinetics of Pazopanib in Combination with Radiotherapy in Patients with Non-Metastatic Soft-Tissue Sarcoma. Cancers, 2021, 13, 5780.	3.7	2
93	Novel longitudinal Multiple Overall Toxicity (MOTox) score to quantify adverse events experienced by patients during chemotherapy treatment: a retrospective analysis of the MRC BO06 trial in osteosarcoma. BMJ Open, 2021, 11, e053456.	1.9	0
94	Prognostic Value of Quantitative [18F]FDG-PET Features in Patients with Metastases from Soft Tissue Sarcoma. Diagnostics, 2021, 11, 2271.	2.6	3
95	Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. Cancer, 2020, 126, 98-104.	4.1	25
96	International evaluation of circumferential resection margins after rectal cancer resection: insights from the Swedish and Dutch audits. Colorectal Disease, 2020, 22, 416-429.	1.4	11
97	Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2020, 18, 69-76.e4.	1.9	11
98	Nationwide analysis of hospital variation in preoperative radiotherapy use for rectal cancer following guideline revision. European Journal of Surgical Oncology, 2020, 46, 486-494.	1.0	14
99	Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib. Future Oncology, 2020, 16, 4251-4264.	2.4	43
100	Which Factors Are Associated with Local Control and Survival of Patients with Localized Pelvic Ewing's Sarcoma? A Retrospective Analysis of Data from the Euro-EWING99 Trial. Clinical Orthopaedics and Related Research, 2020, 478, 290-302.	1.5	45
101	Single-Center Experience with Ifosfamide Monotherapy as Second-Line Treatment of Recurrent/Metastatic Osteosarcoma. Oncologist, 2020, 25, e716-e721.	3.7	8
102	Survival of soft tissue sarcoma patients after completing six cycles of first-line anthracycline containing treatment: an EORTC-STBSG database study. Clinical Sarcoma Research, 2020, 10, 18.	2.3	10
103	Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study. ESMO Open, 2020, 5, e000787.	4.5	22
104	Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. Annals of Oncology, 2020, 31, 1506-1517.	1.2	103
105	Dynamic prediction of overall survival: a retrospective analysis on 979 patients with Ewing sarcoma from the German registry. BMJ Open, 2020, 10, e036376.	1.9	0
106	Age-related differences of oncological outcomes in primary extremity soft tissue sarcoma: a multistate model including 6260 patients. European Journal of Cancer, 2020, 141, 128-136.	2.8	13
107	Unraveling the Resistance of IGF-Pathway Inhibition in Ewing Sarcoma. Cancers, 2020, 12, 3568.	3.7	15
108	Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor. Future Oncology, 2020, 16, 2345-2356.	2.4	22

#	ARTICLE	IF	CITATIONS
109	Genetic Variants in DNA Repair Pathways as Potential Biomarkers in Predicting Treatment Outcome of Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: A Systematic Review. <i>Frontiers in Pharmacology</i> , 2020, 11, 577968.	3.5	4
110	Correlation of the tumour-stroma ratio with diffusion weighted MRI in rectal cancer. <i>European Journal of Radiology</i> , 2020, 133, 109345.	2.6	8
111	Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time. <i>European Journal of Cancer</i> , 2020, 141, 9-20.	2.8	37
112	594P The Drug Rediscovery Protocol (DRUP): Results of the first 500 treated patients. <i>Annals of Oncology</i> , 2020, 31, S498.	1.2	2
113	Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1366-1377.	10.7	266
114	Analysis of Drug Metabolizing Gene Panel in Osteosarcoma Patients Identifies Association Between Variants in SULT1E1, CYP2B6 and CYP4F8 and Methotrexate Levels and Toxicities. <i>Frontiers in Pharmacology</i> , 2020, 11, 1241.	3.5	7
115	Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. <i>Journal of Clinical Oncology</i> , 2020, 38, 3294-3303.	1.6	61
116	Selection of Effective Therapies Using Three-Dimensional in vitro Modeling of Chondrosarcoma. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 566291.	3.5	7
117	1622MO Clinical benefit with ripretinib as 4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS study. <i>Annals of Oncology</i> , 2020, 31, S973-S974.	1.2	1
118	1623MO Ripretinib intra-patient dose escalation (IPDE) following disease progression provides clinically meaningful progression-free survival (PFS) in gastrointestinal stromal tumor (GIST) in phase I study. <i>Annals of Oncology</i> , 2020, 31, S974-S975.	1.2	3
119	1626MO Treatment expectations and preferences for quality versus quantity of life in patients with advanced soft tissue sarcomas starting palliative 1st line chemotherapy. <i>Annals of Oncology</i> , 2020, 31, S976.	1.2	0
120	1594P Harmonising patient-access programmes. <i>Annals of Oncology</i> , 2020, 31, S963.	1.2	0
121	PD-1 Blockade in Anaplastic Thyroid Carcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 2620-2627.	1.6	177
122	The significance of stromal collagen organization in cancer tissue: An in-depth discussion of literature. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102907.	4.4	30
123	Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 â€”CaboGISTâ€™. <i>European Journal of Cancer</i> , 2020, 134, 62-74.	2.8	42
124	Using a quality of life (QoL)-monitor: preliminary results of a randomized trial in Dutch patients with early breast cancer. <i>Quality of Life Research</i> , 2020, 29, 2961-2975.	3.1	5
125	Exposureâ€”response analysis of endoxifen serum concentrations in early-breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 1141-1152.	2.3	10
126	Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 923-934.	10.7	224

#	ARTICLE	IF	CITATIONS
127	Current concepts in the treatment of giant cell tumour of bone. <i>Current Opinion in Oncology</i> , 2020, 32, 332-338.	2.4	21
128	Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study. <i>British Journal of Cancer</i> , 2020, 122, 1158-1165.	6.4	17
129	Quality of treatment and surgical approach for rectal gastrointestinal stromal tumour (GIST) in a large European cohort. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1124-1130.	1.0	26
130	Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. <i>Cancer</i> , 2020, 126, 2637-2647.	4.1	86
131	Treatment strategies and overall survival for incurable metastatic colorectal cancer – A EURECCA international comparison including 21,196 patients from the Netherlands and Norway. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1167-1173.	1.0	5
132	Denosumab salvage therapy in a patient with a locally advanced and refractory sellar giant cell tumour of bone. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 348.	11.4	1
133	Type of surgery in rectal gastrointestinal stromal tumour (GIST) does not affect outcome in a large european cohort. <i>European Journal of Surgical Oncology</i> , 2020, 46, e28.	1.0	0
134	A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors. , 2020, 8, e000530.		54
135	Identification of pharmacogenetic biomarkers for efficacy of cytoreductive surgery plus hyperthermic intraperitoneal mitomycin C in patients with colorectal peritoneal metastases. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1925-1931.	1.0	4
136	Gastrointestinal Stromal Tumours (GIST) in Young Adult (18–40 Years) Patients: A Report from the Dutch GIST Registry. <i>Cancers</i> , 2020, 12, 730.	3.7	15
137	Therapy-Related Imaging Findings in Patients with Sarcoma. <i>Seminars in Musculoskeletal Radiology</i> , 2020, 24, 676-691.	0.7	5
138	Comparison of two chemotherapy regimens in Ewing sarcoma (ES): Overall and subgroup results of the Euro Ewing 2012 randomized trial (EE2012).. <i>Journal of Clinical Oncology</i> , 2020, 38, 11500-11500.	1.6	36
139	Efficacy of add-on treosulfan and melphalan high-dose therapy in patients with high-risk metastatic Ewing sarcoma: Report from the International Ewing 2008R3 trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11501-11501.	1.6	6
140	Efficacy of maintenance therapy with zoledronic acid in patients with localized Ewing sarcoma: Report from the international Ewing 2008 trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11523-11523.	1.6	8
141	Quality of life (QoL) and self-reported function with ripretinib in 4th-line therapy for patients with gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11535-11535.	1.6	8
142	Safety profile of ripretinib, including impact of alopecia, and Palmar-Plantar Erythrodysesthesia Syndrome (PPES) on patient-reported outcomes (PROs), in 4th-line advanced gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11539-11539.	1.6	3
143	Olaparib monotherapy in pretreated patients with BRCA1/2 alterations: Results of a DRUP trial cohort.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3633-3633.	1.6	1
144	Therapeutic drug monitoring of pazopanib: Using cost-neutral PK-guided interventions to optimize exposure.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3598-3598.	1.6	1

#	ARTICLE	IF	CITATIONS
145	Activity of cabazitaxel in patients with metastatic or inoperable locally advanced dedifferentiated liposarcoma: European Organization for Research and Treatment of Cancer (EORTC) Phase II trial 1202.. Journal of Clinical Oncology, 2020, 38, 11556-11556.	1.6	0
146	Patient journey and quality of life (QOL) among diffuse-type TGCT in the U.S.. Journal of Clinical Oncology, 2020, 38, e23565-e23565.	1.6	0
147	1627MO Systemic therapies in advanced epithelioid haemangioendothelioma (EHE): A retrospective international series from the World Sarcoma Network. Annals of Oncology, 2020, 31, S977.	1.2	0
148	Ototoxicity in locally advanced head and neck cancer patients treated with induction chemotherapy followed by intermediate or high-dose cisplatin-based chemoradiotherapy. Head and Neck, 2019, 41, 488-494.	2.0	6
149	Outcome of First-Line Systemic Treatment for Unresectable Conventional, Dedifferentiated, Mesenchymal, and Clear Cell Chondrosarcoma. Oncologist, 2019, 24, 110-116.	3.7	34
150	Individual risk evaluation for local recurrence and distant metastasis in Ewing sarcoma: A multistate model. Pediatric Blood and Cancer, 2019, 66, e27943.	1.5	17
151	Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses. BMC Cancer, 2019, 19, 794.	2.6	20
152	Easy-to-use clinical tool for survival estimation in Ewing sarcoma at diagnosis and after surgery. Scientific Reports, 2019, 9, 11000.	3.3	13
153	The effect of gastrectomy on regorafenib exposure and progression-free survival in patients with advanced gastrointestinal stromal tumours. British Journal of Clinical Pharmacology, 2019, 85, 2399-2404.	2.4	5
154	Pexidartinib (Pex) for locally advanced tenosynovial giant cell tumour (TGCT): Characterization of hepatic adverse reactions (ARs). Annals of Oncology, 2019, 30, v695-v696.	1.2	4
155	INVICTUS: A phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as a 4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (NCT03353753). Annals of Oncology, 2019, 30, v925-v926.	1.2	11
156	Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor. Scientific Reports, 2019, 9, 14551.	3.3	41
157	Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncology, The, 2019, 20, 1719-1729.	10.7	143
158	High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008. Journal of Clinical Oncology, 2019, 37, 3192-3202.	1.6	84
159	Therapeutic drug monitoring of oral anticancer drugs - preliminary results of a prospective study. Annals of Oncology, 2019, 30, v161.	1.2	3
160	Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. European Journal of Cancer, 2019, 109, 36-50.	2.8	354
161	The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. European Journal of Cancer, 2019, 109, 51-60.	2.8	134
162	Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors. Pharmacogenomics Journal, 2019, 19, 473-479.	2.0	9

#	ARTICLE	IF	CITATIONS
163	Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. <i>Lancet</i> , The, 2019, 394, 478-487.	13.7	273
164	Reply to C.L. Braal et al, H. Brauch et al, and M.P. Goetz et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 1984-1985.	1.6	2
165	The Effect of Using Pazopanib With Food vs. Fasted on Pharmacokinetics, Patient Safety, and Preference (<scp>DIET</scp> Study). <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1076-1082.	4.7	26
166	Survival and Cost-Effectiveness of Trabectedin Compared to Ifosfamide Monotherapy in Advanced Soft Tissue Sarcoma Patients. <i>Sarcoma</i> , 2019, 2019, 1-11.	1.3	1
167	Adjuvant Zoledronic Acid in High-Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial. <i>Oncologist</i> , 2019, 24, 889-e421.	3.7	16
168	Stromal organization as predictive biomarker for the treatment of colon cancer with adjuvant bevacizumab; a post-hoc analysis of the AVANT trial. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 717-725.	4.4	4
169	Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 523-536.	3.1	60
170	Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study. <i>Lancet Oncology</i> , The, 2019, 20, 877-886.	10.7	75
171	¹⁸ F-FDG PET-CT versus MRI for detection of skeletal metastasis in Ewing sarcoma. <i>Skeletal Radiology</i> , 2019, 48, 1735-1746.	2.0	18
172	Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients. <i>Annals of Oncology</i> , 2019, 30, 663-665.	1.2	21
173	A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAbâ€œ004) in metastatic soft-tissue sarcomas. <i>Cancer</i> , 2019, 125, 2445-2454.	4.1	19
174	Association of pazopanib-induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective analysis based on the European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials. <i>Acta Oncologica</i> , 2019, 58, 872-879.	1.8	11
175	Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 636-646.	1.6	72
176	A novel method to address the association between received dose intensity and survival outcome: benefits of approaching treatment intensification at a more individualised level in a trial of the European Osteosarcoma Intergroup. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 951-962.	2.3	20
177	Impact of Concomitant Administration of Gastric Acidâ€œSuppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials. <i>Clinical Cancer Research</i> , 2019, 25, 1479-1485.	7.0	63
178	Method to measure the mismatch between target and achieved received dose intensity of chemotherapy in cancer trials: a retrospective analysis of the MRC BO06 trial in osteosarcoma. <i>BMJ Open</i> , 2019, 9, e022980.	1.9	5
179	Home treatment of patients with cancer-associated venous thromboembolism â€œ An evaluation of daily practice. <i>Thrombosis Research</i> , 2019, 184, 122-128.	1.7	11
180	The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs. <i>Nature</i> , 2019, 574, 127-131.	27.8	152

#	ARTICLE	IF	CITATIONS
181	Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone. Current Opinion in Oncology, 2019, 31, 329-335.	2.4	55
182	A cost analysis of upfront DPYD genotypeâ€“guided dose individualisation in fluoropyrimidine-based anticancer therapy. European Journal of Cancer, 2019, 107, 60-67.	2.8	65
183	Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients. Clinical Pharmacokinetics, 2019, 58, 651-658.	3.5	20
184	Surgical and medical management of small bowel gastrointestinal stromal tumors: A report of the Dutch GIST registry. European Journal of Surgical Oncology, 2019, 45, 410-415.	1.0	7
185	STRASS (EORTC 62092): A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with retroperitoneal sarcoma.. Journal of Clinical Oncology, 2019, 37, 11001-11001.	1.6	64
186	Activity and safety of cabozantinib in patients with gastrointestinal stromal tumor after failure of imatinib and sunitinib: EORTC phase II trial 1317 CaboGIST.. Journal of Clinical Oncology, 2019, 37, 11006-11006.	1.6	9
187	ALT-GIST: Randomized phase II trial of imatinib alternating with regorafenib versus imatinib alone for the first-line treatment of metastatic gastrointestinal stromal tumor (GIST).. Journal of Clinical Oncology, 2019, 37, 11023-11023.	1.6	9
188	Pexidartinib for advanced tenosynovial giant cell tumor (TGCT): Long-term efficacy and safety from the phase 3 ENLIVEN and phase 1 PLX108-01 (TGCT cohort) studies.. Journal of Clinical Oncology, 2019, 37, 11042-11042.	1.6	4
189	A reduced pazopanib dose with food: Is it more patient-friendly and does it reduce drug costs?. Journal of Clinical Oncology, 2019, 37, 4564-4564.	1.6	2
190	The impact of gastric acid suppressive agents on pazopanib exposure.. Journal of Clinical Oncology, 2019, 37, e16076-e16076.	1.6	1
191	Responder analysis of patient-reported outcomes measurement information system (PROMIS) physical function (PF) and worst stiffness among patients with tenosynovial giant cell tumors (TGCT) in the ENLIVEN study.. Journal of Clinical Oncology, 2019, 37, e18236-e18236.	1.6	1
192	Update on the Drug Rediscovery Protocol: Expanded use of existing anticancer drugs in patients with a known molecular profile.. Journal of Clinical Oncology, 2019, 37, TPS3149-TPS3149.	1.6	0
193	The effect of gastrectomy in regorafenib treated GIST patients on outcome and drug exposure.. Journal of Clinical Oncology, 2019, 37, e22511-e22511.	1.6	0
194	The tumourâ€“stroma ratio in colon cancer: the biological role and its prognostic impact. Histopathology, 2018, 73, 197-206.	2.9	97
195	Recurrence of Ewing sarcoma: Is detection by imaging followâ€“up protocol associated with survival advantage?. Pediatric Blood and Cancer, 2018, 65, e27011.	1.5	22
196	A Genetic Polymorphism in <i>CTLA-4</i> Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2018, 24, 2350-2356.	7.0	7
197	Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and) Tj ETQq1 1 0.784314,rgBT /Overlock 10.7 134	10.7	134
198	Mechanistic Insights of an Immunological Adverse Event Induced by an Anti-KIT Antibody Drug Conjugate and Mitigation Strategies. Clinical Cancer Research, 2018, 24, 3465-3474.	7.0	21

#	ARTICLE	IF	CITATIONS
199	Denosumab treatment of inoperable or locally advanced giant cell tumor of bone – Multicenter analysis outside clinical trial. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1384-1390.	1.0	70
200	Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma. <i>JAMA Oncology</i> , 2018, 4, e180219.	7.1	63
201	Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials. <i>Oncologist</i> , 2018, 23, 1250-1259.	3.7	25
202	Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC-SoftTBSG). <i>International Journal of Cancer</i> , 2018, 142, 2610-2620.	5.1	32
203	The incidence, mutational status, risk classification and referral pattern of gastro-intestinal stromal tumours in the Netherlands: a nationwide pathology registry (PALGA) study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 221-229.	2.8	39
204	Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 – CREATE™. <i>Annals of Oncology</i> , 2018, 29, 758-765.	1.2	67
205	Prognostic relevance of distant metastases versus locally advanced disease in soft tissue sarcomas: An EORTC-STBSG database study. <i>European Journal of Cancer</i> , 2018, 94, 187-198.	2.8	6
206	Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma. <i>Clinical Cancer Research</i> , 2018, 24, 2678-2687.	7.0	35
207	Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 639-648.	10.7	81
208	Predictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-soft tissue and bone sarcoma group database. <i>Acta Oncologica</i> , 2018, 57, 1117-1126.	1.8	11
209	Genetic polymorphisms as predictive biomarker of survival in patients with gastrointestinal stromal tumors treated with sunitinib. <i>Pharmacogenomics Journal</i> , 2018, 18, 49-55.	2.0	8
210	Early Evaluation of Response Using 18F-FDG PET Influences Management in Gastrointestinal Stromal Tumor Patients Treated with Neoadjuvant Imatinib. <i>Journal of Nuclear Medicine</i> , 2018, 59, 194-196.	5.0	24
211	Are pathological high-risk features in locally advanced rectal cancer a useful selection tool for adjuvant chemotherapy?. <i>European Journal of Cancer</i> , 2018, 89, 1-8.	2.8	18
212	Quality of life of patients with locally advanced head and neck cancer treated with induction chemotherapy followed by cisplatin-containing chemoradiotherapy in the Dutch CONDOR study: a randomized controlled trial. <i>Supportive Care in Cancer</i> , 2018, 26, 1233-1242.	2.2	5
213	Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. <i>Oncologist</i> , 2018, 23, 62-70.	3.7	62
214	Perioperative Management of Extremity Soft Tissue Sarcomas. <i>Journal of Clinical Oncology</i> , 2018, 36, 118-124.	1.6	33
215	High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008. <i>Journal of Clinical Oncology</i> , 2018, 36, 3110-3119.	1.6	107
216	Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab. <i>PLoS ONE</i> , 2018, 13, e0208080.	2.5	7

#	ARTICLE	IF	CITATIONS
217	Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD Variants. <i>Genes</i> , 2018, 9, 585.	2.4	10
218	Bone sarcomas: ESMOâ€œPaedCanâ€œEURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv79-iv95.	1.2	380
219	Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone. <i>World Journal of Surgical Oncology</i> , 2018, 16, 191.	1.9	39
220	Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers. <i>European Journal of Cancer</i> , 2018, 104, 210-218.	2.8	14
221	DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. <i>Lancet Oncology</i> , The, 2018, 19, 1459-1467.	10.7	238
222	DPYD genotype-guided dose individualization of fluoropyrimidine therapy: A prospective safety and cost-analysis on DPYD variants DPYD*2A, c.2846A>T, c.1679T>G and c.1236G>A. <i>Annals of Oncology</i> , 2018, 29, viii150.	1.2	13
223	Chordoma: a systematic review of the epidemiology and clinical prognostic factors predicting progression-free and overall survival. <i>European Spine Journal</i> , 2018, 27, 3043-3058.	2.2	96
224	Outcome of Nonsurgical Management of Extra-Abdominal, Trunk, and Abdominal Wall Desmoid-Type Fibromatosis: A Population-Based Study in the Netherlands. <i>Sarcoma</i> , 2018, 2018, 1-8.	1.3	14
225	Gastrointestinal stromal tumours: ESMOâ€œEURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv68-iv78.	1.2	413
226	Soft tissue and visceral sarcomas: ESMOâ€œEURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv51-iv67.	1.2	641
227	HLA-G protein expression in colorectal cancer evaluated by immunohistochemistry and western blot analysis: Its expression characteristics remain enigmatic. <i>Clinical Immunology</i> , 2018, 194, 80-86.	3.2	26
228	Incidence and demographics of giant cell tumor of bone in The Netherlands: First nationwide Pathology Registry Study. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2018, 89, 570-574.	3.3	39
229	A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case report. <i>BMC Cancer</i> , 2018, 18, 92.	2.6	15
230	Pharmacokinetics and safety of panitumumab in a patient with chronic kidney disease. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 179-182.	2.3	10
231	Genetic polymorphisms of 3â€²-untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 401-411.	2.5	22
232	Prognostic factors for survival in Ewing sarcoma: A systematic review. <i>Surgical Oncology</i> , 2018, 27, 603-610.	1.6	81
233	Achievements in colorectal cancer care during 8 years of auditing in The Netherlands. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1361-1370.	1.0	47
234	Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT).. <i>Journal of Clinical Oncology</i> , 2018, 36, 11502-11502.	1.6	16

#	ARTICLE	IF	CITATIONS
235	Prognostic stratification using the nomogram sarcuator and its impact on study results in a randomized controlled trial (RCT) for localized soft tissue sarcomas (STS): A secondary analysis of the EORTC-STBSG 62931.. Journal of Clinical Oncology, 2018, 36, 11518-11518.	1.6	5
236	First prospective observational study in diffuse-type tenosynovial giant cell tumors.. Journal of Clinical Oncology, 2018, 36, 11560-11560.	1.6	2
237	Doxorubicin plus dacarbazine (DoDa), doxorubicin plus ifosfamide (DI) or doxorubicin alone (Do) as first line treatment for advanced leiomyosarcoma (LMS): A retrospective study from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG).. Journal of Clinical Oncology, 2018, 36, 11574-11574.	1.6	6
238	A prospective study on the effect of endoxifen concentration and CYP2D6 phenotypes on clinical outcome in early stage breast cancer patients receiving adjuvant tamoxifen.. Journal of Clinical Oncology, 2018, 36, 523-523.	1.6	3
239	Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with anaplastic thyroid cancer.. Journal of Clinical Oncology, 2018, 36, 6024-6024.	1.6	38
240	A single digital droplet PCR assay to detect multiple <i>KIT</i> exon 11 mutations in tumor and plasma from patients with gastrointestinal stromal tumors. Oncotarget, 2018, 9, 13870-13883.	1.8	28
241	Surrogate endpoints in advanced sarcoma trials: a meta-analysis. Oncotarget, 2018, 9, 34617-34627.	1.8	9
242	Survival outcomes from a cumulative analysis from worldwide observational studies on sequential use of new agents (NAs) in metastatic castration-resistant prostate cancer (mCRPC) (CASTOR study).. Journal of Clinical Oncology, 2018, 36, 5026-5026.	1.6	0
243	Activity and safety of crizotinib in patients with advanced, metastatic alveolar soft part sarcoma (ASPS) with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 CREATE.. Journal of Clinical Oncology, 2018, 36, 11540-11540.	1.6	1
244	Everolimus in patients with advanced follicular-derived thyroid cancer; results of a phase II clinical trial.. Journal of Clinical Endocrinology and Metabolism, 2017, 102, jc.2016-2525.	3.6	55
245	Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma. Pharmacogenomics Journal, 2017, 17, 42-46.	2.0	21
246	Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE) Tj ETQq0 010rgBT /Overlock 10		
247	Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients. European Journal of Cancer, 2017, 76, 76-83.	2.8	32
248	A phase II study of a human anti-PDGFR α monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors. Annals of Oncology, 2017, 28, 541-546.	1.2	39
249	Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma. Pharmacogenetics and Genomics, 2017, 27, 227-231.	1.5	5
250	Short-Course Radiotherapy Followed by Neoadjuvant Bevacizumab, Capecitabine, and Oxaliplatin and Subsequent Radical Treatment in Primary Stage IV Rectal Cancer: Long-Term Results of a Phase II Study. Annals of Surgical Oncology, 2017, 24, 2632-2638.	1.5	44
251	Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with <i>IDH1</i> -mutated or <i>IDH2</i> -mutated solid tumours. BMJ Open, 2017, 7, e014961.	1.9	69
252	Giant cell tumour of bone in the denosumab era. European Journal of Cancer, 2017, 77, 75-83.	2.8	117

#	ARTICLE	IF	CITATIONS
253	Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group. <i>Annals of Oncology</i> , 2017, 28, 1230-1242.	1.2	168
254	Influenza vaccination in adult patients with solid tumours treated with chemotherapy. <i>European Journal of Cancer</i> , 2017, 76, 134-143.	2.8	36
255	Central venous access related adverse events after trabectedin infusions in soft tissue sarcoma patients; experience and management in a nationwide multi-center study. <i>Clinical Sarcoma Research</i> , 2017, 7, 2.	2.3	8
256	Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil. <i>Journal of Gastrointestinal Cancer</i> , 2017, 48, 117-118.	1.3	1
257	Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands. <i>European Journal of Cancer</i> , 2017, 72, 156-165.	2.8	77
258	Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib. <i>European Journal of Cancer</i> , 2017, 86, 226-232.	2.8	13
259	Higher incidence rates than previously known in tenosynovial giant cell tumors. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2017, 88, 688-694.	3.3	87
260	Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 1589-1598.	1.9	43
261	Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study. <i>Acta Oncologica</i> , 2017, 56, 1769-1775.	1.8	29
262	The effect of rs5758550 on CYP2D6*2 phenotype and formation of endoxifen in breast cancer patients using tamoxifen. <i>Pharmacogenomics</i> , 2017, 18, 1125-1132.	1.3	19
263	Does a glass of Coke boost the exposure to imatinib in gastrointestinal stromal tumour patients after gastrectomy?. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2312-2314.	2.4	7
264	High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor Growth. <i>Translational Oncology</i> , 2017, 10, 546-554.	3.7	11
265	Pharmacogenetics of Chemotherapy Response in Osteosarcoma: A Genetic Variant in SLC7A8 is Associated with Progressive Disease. <i>Clinical Therapeutics</i> , 2017, 39, e10.	2.5	2
266	Should rectal cancer located 10â€“15â€‰cm from the anal verge be defined as colon cancer. <i>Annals of Oncology</i> , 2017, 28, 664-665.	1.2	4
267	Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. <i>Acta Oncologica</i> , 2017, 56, 88-92.	1.8	146
268	Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults. <i>Head and Neck</i> , 2017, 39, 140-146.	2.0	48
269	Expanding the use of approved drugs: The CPCT's Drug Rediscovery Protocol (DRUP). <i>Annals of Oncology</i> , 2017, 28, v649.	1.2	0
270	Expanding the use of approved drugs: The CPCT's Drug Rediscovery Protocol (DRUP). <i>Annals of Oncology</i> , 2017, 28, x1.	1.2	0

#	ARTICLE	IF	CITATIONS
271	Tumor LINE-1 Methylation Level in Association with Survival of Patients with Stage II Colon Cancer. International Journal of Molecular Sciences, 2017, 18, 36.	4.1	29
272	Safety and efficacy of pazopanib (PAZ) in advanced soft tissue carcinoma (aSTS) by prior lines of therapy, age, and dose modifications: PALETTE subgroup analyses. Annals of Oncology, 2017, 28, v530-v531.	1.2	0
273	Evaluation of Quality of Life at Progression in Patients with Soft Tissue Sarcoma. Sarcoma, 2017, 2017, 1-8.	1.3	20
274	Limb Amputation after Multiple Treatments of Tenosynovial Giant Cell Tumour: Series of 4 Dutch Cases. Case Reports in Orthopedics, 2017, 2017, 1-6.	0.3	10
275	Long-term efficacy of denosumab in giant cell tumor of bone: Results of an open-label phase 2 study. Annals of Oncology, 2017, 28, v645-v646.	1.2	3
276	Serum levels of IGF-1 and IGF-BP3 are associated with event-free survival in adult Ewing sarcoma patients treated with chemotherapy. OncoTargets and Therapy, 2017, Volume 10, 2963-2970.	2.0	12
277	Neoadjuvant denosumab treatment of locally advanced giant cell tumor of bone (GCTB).. Journal of Clinical Oncology, 2017, 35, 11026-11026.	1.6	2
278	Anthracycline, gemcitabine, and pazopanib in epithelioid sarcoma: Results of a retrospective multi-institutional case series.. Journal of Clinical Oncology, 2017, 35, 11065-11065.	1.6	2
279	A phase I/II dose escalation and expansion study of cabiralizumab (cabira; FPA-008), an anti-CSF1R antibody, in tenosynovial giant cell tumor (TGCT, diffuse pigmented villonodular synovitis D-PVNS).. Journal of Clinical Oncology, 2017, 35, 11078-11078.	1.6	26
280	Meta-analysis on the association of <i>VEGFR1</i> genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients. Oncotarget, 2017, 8, 1204-1212.	1.8	6
281	The Drug Rediscovery Protocol (DRUP).. Journal of Clinical Oncology, 2017, 35, 2547-2547.	1.6	0
282	Tissue factor associates with survival and regulates tumour progression in osteosarcoma. Thrombosis and Haemostasis, 2016, 115, 1025-1033.	3.4	23
283	Panobinostatâ€”A Potential Treatment for Metastasized Ewing Sarcoma? A Case Report. Pediatric Blood and Cancer, 2016, 63, 1840-1843.	1.5	7
284	Evaluation of an oral uracil loading test to identify DPDâ€”deficient patients using a limited sampling strategy. British Journal of Clinical Pharmacology, 2016, 81, 553-561.	2.4	26
285	Molecular oncogenesis of chondrosarcoma: impact for targeted treatment. Current Opinion in Oncology, 2016, 28, 314-322.	2.4	43
286	Evaluation of clinical implementation of prospective <i>DPYD</i> genotyping in 5-fluorouracil- or capecitabine-treated patients. Pharmacogenomics, 2016, 17, 721-729.	1.3	24
287	Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSC) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy. Gynecologic Oncology, 2016, 142, 95-101.	1.4	14
288	Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy. British Journal of Cancer, 2016, 114, 1219-1226.	6.4	13

#	ARTICLE	IF	CITATIONS
289	Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer. <i>Oncology</i> , 2016, 91, 267-273.	1.9	10
290	52. Resection of the primary tumour for asymptomatic incurable metastatic colorectal cancer – A EURECCA international comparison. <i>European Journal of Surgical Oncology</i> , 2016, 42, S86-S87.	1.0	0
291	Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone. <i>Clinical Sarcoma Research</i> , 2016, 6, 15.	2.3	80
292	Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation. <i>Prostate</i> , 2016, 76, 32-40.	2.3	13
293	Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. <i>Lancet Oncology</i> , The, 2016, 17, 1396-1408.	10.7	356
294	Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line. <i>Laboratory Investigation</i> , 2016, 96, 1128-1137.	3.7	31
295	Ototoxicity in locally advanced head and neck cancer (LAHNC) patients (pts) treated with induction chemotherapy (IC) followed by cisplatin-based chemoradiotherapy (CRT). <i>Annals of Oncology</i> , 2016, 27, vi341.	1.2	1
296	Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series. <i>Clinical Sarcoma Research</i> , 2016, 6, 19.	2.3	23
297	Promoter methylation and mRNA expression of HLA-G in relation to HLA-G protein expression in colorectal cancer. <i>Human Immunology</i> , 2016, 77, 764-772.	2.4	9
298	Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 63-71.	2.3	34
299	Insulin-like growth factor 1 receptor expression and IGF1R 3129G>T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01). <i>Breast Cancer Research</i> , 2016, 18, 3.	5.0	30
300	Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 243-247.	1.5	42
301	HLA-G and classical HLA class I expression in primary colorectal cancer and associated liver metastases. <i>Human Immunology</i> , 2016, 77, 773-779.	2.4	39
302	Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. <i>Lancet</i> , The, 2016, 387, 1629-1637.	13.7	610
303	Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway. <i>European Journal of Cancer</i> , 2016, 53, 171-180.	2.8	38
304	A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 605-618.	3.1	19
305	Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial. <i>BMC Cancer</i> , 2016, 16, 22.	2.6	52
306	Drug-drug interactions associated with kinase inhibitors: highlighting a new resource for oncologists and clinical pharmacists. <i>Annals of Oncology</i> , 2016, 27, 752.	1.2	1

#	ARTICLE	IF	CITATIONS
307	Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of CancerÂSoft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity. <i>European Journal of Cancer</i> , 2016, 58, 62-72.	2.8	114
308	Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study. <i>European Journal of Cancer</i> , 2016, 52, 77-84.	2.8	35
309	Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time. <i>European Journal of Cancer</i> , 2016, 54, 40-48.	2.8	110
310	Xerosis and pruritus as major EGFR-associated adverse events. <i>Supportive Care in Cancer</i> , 2016, 24, 513-521.	2.2	45
311	Clinical characteristics and treatment outcome in a large multicenter observational cohort of pdgfra exon 18 mutated gastrointestinal stromal tumor (GIST) patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11011-11011.	1.6	1
312	Prognostic factors for local control in Ewing sarcoma (ES) in the Euro-EWING99 trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11026-11026.	1.6	2
313	Food intervention to make therapy with pazopanib more patient-friendly and affordable.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11040-11040.	1.6	3
314	A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3060-3060.	1.6	11
315	A phase I study in patients with a human papillomavirus type 16 positive oropharyngeal tumor treated with second generation synthetic long peptide vaccine conjugated to a defined adjuvant.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS3113-TPS3113.	1.6	9
316	Evaluation of quality of life at progression in patients with soft tissue sarcoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11015-11015.	1.6	0
317	Causal effects of methotrexate reductions/delays in treatment of high-grade resectable osteosarcoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, e22502-e22502.	1.6	0
318	Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: Secondary analysis of the Euro-Ewing99-R1 trial. <i>European Journal of Cancer</i> , 2015, 51, 2453-2464.	2.8	21
319	Safety and efficacy of the addition of simvastatin to panitumumab in previously treated KRAS mutant metastatic colorectal cancer patients. <i>Anti-Cancer Drugs</i> , 2015, 26, 872-877.	1.4	15
320	Radiation-induced Sarcomas Occurring in Desmoid-type Fibromatosis Are Not Always Derived From the Primary Tumor. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1701-1707.	3.7	4
321	Imatinib-induced agranulocytosis in patients with gastrointestinal stromal tumors. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 920-925.	2.0	2
322	Dried blood spot analysis for therapeutic drug monitoring of pazopanib. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 1344-1350.	2.0	26
323	Therapeutic Drug Monitoring to Individualize the Dosing of Pazopanib. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 331-338.	2.0	48
324	Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2015, 10, e0131091.	2.5	13

#	ARTICLE	IF	CITATIONS
325	Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial. <i>International Journal of Endocrinology</i> , 2015, 2015, 1-8.	1.5	42
326	Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2279-2287.	1.6	329
327	Further characterization of a ¹³ C-dextromethorphan breath test for CYP2D6 phenotyping in breast cancer patients on tamoxifen therapy. <i>Journal of Breath Research</i> , 2015, 9, 026003.	3.0	7
328	Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. <i>Journal of Clinical Oncology</i> , 2015, 33, 4276-4283.	1.6	148
329	CYP2D6 Metabolism in Frail Elderly Compared to Non-Frail Elderly: A Pilot Feasibility Study. <i>Drugs and Aging</i> , 2015, 32, 1019-1027.	2.7	11
330	Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial. <i>Annals of Oncology</i> , 2015, 26, vi48.	1.2	0
331	EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. <i>Annals of Oncology</i> , 2015, 26, 407-414.	1.2	230
332	Clinical outcomes of patients with advanced gastrointestinal stromal tumors: Safety and efficacy in a worldwide treatment-free trial of sunitinib. <i>Cancer</i> , 2015, 121, 1405-1413.	4.1	89
333	A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 87-95.	2.3	40
334	Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event) <i>TJ ETQq0 0 0 rgBT / Overlock 10 Tf 50 37</i>	0.2	10
335	Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 47-52.	2.3	7
336	CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel. <i>International Journal of Cancer</i> , 2015, 136, E760-72.	5.1	34
337	CYP3A5 and ABCB1 Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2015, 68, 621-629.	1.9	75
338	A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment. <i>Clinical Cancer Research</i> , 2015, 21, 3436-3441.	7.0	34
339	Development of a Pharmacokinetic Model of Mitotane. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 58-65.	2.0	22
340	CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 583-590.	2.5	54
341	Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients. <i>Investigational New Drugs</i> , 2015, 33, 1242-1247.	2.6	26
342	Randomised study of tegafur-uracil plus leucovorin versus capecitabine as first-line therapy in elderly patients with advanced colorectal cancer - TLC study. <i>Journal of Geriatric Oncology</i> , 2015, 6, 307-315.	1.0	15

#	ARTICLE	IF	CITATIONS
343	A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities. <i>Acta Oncologica</i> , 2015, 54, 1195-1201.	1.8	53
344	Healthcare utilisation in patients with breast cancer or non-Hodgkin lymphoma who experienced febrile neutropenia in the Netherlands: a retrospective matched control study using the PHARMO database. <i>European Journal of Cancer Care</i> , 2015, 24, 232-241.	1.5	6
345	Translating <i>CYP2D6</i> genotype into DPD phenotype: using the <i>CYP2D6</i> gene activity score. <i>Pharmacogenomics</i> , 2015, 16, 1275-1284.	1.3	81
346	Exploratory analysis of candidate germline gene polymorphisms in breast cancer patients treated with neoadjuvant anthracycline-containing chemotherapy and associations with febrile neutropenia. <i>Pharmacogenomics</i> , 2015, 16, 1265-1274.	1.3	4
347	Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1477-1484.	1.9	19
348	Neoadjuvant denosumab for extensive giant cell tumor in os ischium – a case report. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2015, 86, 393-395.	3.3	14
349	Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. <i>Annals of Oncology</i> , 2015, 26, 696-701.	1.2	302
350	Etoposide and carboplatin combination therapy in refractory or relapsed Ewing sarcoma: A large retrospective study. <i>Pediatric Blood and Cancer</i> , 2015, 62, 40-44.	1.5	18
351	Individualized dosing of tyrosine kinase inhibitors: are we there yet?. <i>Drug Discovery Today</i> , 2015, 20, 18-36.	6.4	72
352	Event-free survival and overall survival in 2,253 patients with osteosarcoma registered to EURAMOS-1. <i>Journal of Clinical Oncology</i> , 2015, 33, 10512-10512.	1.6	4
353	Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI). <i>Journal of Clinical Oncology</i> , 2015, 33, LBA10502-LBA10502.	1.6	3
354	Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI). <i>Journal of Clinical Oncology</i> , 2015, 33, LBA10502-LBA10502.	1.6	22
355	<i>CYP3A5</i> and <i>ABCB1</i> polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 4548-4548.	1.6	0
356	Imatinib mesylate (IM) activity in patients (pts) with locally advanced tenosynovial giant cell tumor/pigmented villonodular synovitis (TGCT). <i>Journal of Clinical Oncology</i> , 2015, 33, 10561-10561.	1.6	0
357	Pharmacogenetic markers for efficacy and toxicity of chemotherapy in osteosarcoma patients. <i>Journal of Clinical Oncology</i> , 2015, 33, 10054-10054.	1.6	0
358	Association of pharmacogenetic variants with progressive disease in osteosarcoma patients. <i>Journal of Clinical Oncology</i> , 2015, 33, 10057-10057.	1.6	0
359	Association of hematological toxicity (tox) and outcome to doxorubicin (DOX) in advanced soft tissue sarcoma (STS): A retrospective analysis of the EORTC-Soft Tissue and Bone Sarcoma Group database. <i>Journal of Clinical Oncology</i> , 2015, 33, 10544-10544.	1.6	0
360	A study of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft tissue sarcoma. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS10577-TPS10577.	1.6	1

#	ARTICLE	IF	CITATIONS
361	Investigating the heterogeneity of alkylating agentsâ€™ efficacy between genders: A meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study).. Journal of Clinical Oncology, 2015, 33, e21500-e21500.	1.6	0
362	Identifying Biological and Clinical Characteristics of Patients with Gastrointestinal Stromal Tumours (Gist) Responding to Imatinib Therapy for More Than 5 and 10 Years. Annals of Oncology, 2014, 25, iv500.	1.2	0
363	Association Analysis of Genetic Polymorphisms in Genes Related to Sunitinib Pharmacokinetics, Specifically Clearance of Sunitinib and SU12662. Clinical Pharmacology and Therapeutics, 2014, 96, 81-89.	4.7	67
364	Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: a single reference centre case series. Clinical Sarcoma Research, 2014, 4, 14.	2.3	44
365	The Clinical Approach Toward Giant Cell Tumor of Bone. Oncologist, 2014, 19, 550-561.	3.7	199
366	A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function. Cancer Chemotherapy and Pharmacology, 2014, 74, 1089-1098.	2.3	38
367	Outcome of advanced, unresectable conventional central chondrosarcoma. Cancer, 2014, 120, 3159-3164.	4.1	83
368	Short-term variation in plasma mitotane levels confirms the importance of trough level monitoring. European Journal of Endocrinology, 2014, 171, 677-683.	3.7	13
369	Histone deacetylase inhibitors. Anti-Cancer Drugs, 2014, 25, 140-149.	1.4	130
370	Current clinical trials for advanced osteosarcoma and soft tissue sarcoma. Current Opinion in Oncology, 2014, 26, 434-439.	2.4	12
371	Phase II Multicenter Clinical Trial of Pulmonary Metastasectomy and Isolated Lung Perfusion with Melphalan in Patients with Resectable Lung Metastases. Journal of Thoracic Oncology, 2014, 9, 1547-1553.	1.1	31
372	In Reply. Oncologist, 2014, 19, 1208-1208.	3.7	0
373	Brastallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study. European Journal of Cancer, 2014, 50, 388-396.	2.8	34
374	Excision Repair Cross-Complementation group 1 (ERCC1) C118T SNP does not affect cellular response to oxaliplatin. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2014, 759, 37-44.	1.0	11
375	CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial. Breast Cancer Research and Treatment, 2014, 143, 171-179.	2.5	13
376	Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer. Cancer Chemotherapy and Pharmacology, 2014, 73, 87-96.	2.3	24
377	Pharmacokinetics of panitumumab in a patient with liver dysfunction: a case report. Cancer Chemotherapy and Pharmacology, 2014, 73, 429-433.	2.3	10
378	Prognostic Role of Overt Hypercortisolism in Completely Operated Patients with Adrenocortical Cancer. European Urology, 2014, 65, 832-838.	1.9	121

#	ARTICLE	IF	CITATIONS
379	Pharmacogenetics in the Cancer Clinic: From Candidate Gene Studies to Next-Generation Sequencing. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 383-385.	4.7	14
380	Isolated hepatic perfusion with oxaliplatin combined with 100Âmg melphalan in patients with metastases confined to the liver: A phase I study. <i>European Journal of Surgical Oncology</i> , 2014, 40, 1557-1563.	1.0	15
381	Effect of gastrointestinal resection on sunitinib exposure in patients with GIST. <i>BMC Cancer</i> , 2014, 14, 575.	2.6	13
382	Comprehensive analysis of published studies involving systemic treatment for chondrosarcoma of bone between 2000 and 2013. <i>Clinical Sarcoma Research</i> , 2014, 4, 11.	2.3	33
383	Pharmacokinetics and safety of cetuximab in a patient with renal dysfunction. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 1303-1306.	2.3	12
384	Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 599-606.	2.5	34
385	Primary Ewing sarcoma of the iris. <i>Lancet, The</i> , 2014, 383, 256.	13.7	2
386	Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. <i>Lancet Oncology, The</i> , 2014, 15, 415-423.	10.7	864
387	Phase 1/2A Study of Glutathione Pegylated Liposomal Doxorubicin (2B3-101) in Patients with Brain Metastases (Bm) from Solid Tumors or Recurrent High Grade Gliomas (Hgg). <i>Annals of Oncology</i> , 2014, 25, iv157.	1.2	15
388	Association of genetic variants involved in drug metabolism and transport with efficacy and toxicity of chemotherapeutic treatment in osteosarcoma patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10038-10038.	1.6	1
389	Correlation of <i>KIT</i> and <i>PDGFRA</i> mutational status with clinical benefit in patients (pts) with gastrointestinal stromal tumor (GIST) treated with sunitinib (SU) in a worldwide treatment-use (TU) trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10549-10549.	1.6	1
390	Statin Use Is Not Associated with Improved Progression Free Survival in Cetuximab Treated KRAS Mutant Metastatic Colorectal Cancer Patients: Results from the CAIRO2 Study. <i>PLoS ONE</i> , 2014, 9, e112201.	2.5	31
391	Influence of Genetic Variants in TPMT and COMT Associated with Cisplatin Induced Hearing Loss in Patients with Cancer: Two New Cohorts and a Meta-Analysis Reveal Significant Heterogeneity between Cohorts. <i>PLoS ONE</i> , 2014, 9, e115869.	2.5	47
392	Nuclear Eg5 (kinesin spindle protein) expression predicts docetaxel response and prostate cancer aggressiveness. <i>Oncotarget</i> , 2014, 5, 7357-7367.	1.8	24
393	Quality of life of patients with locally advanced head and neck cancer (LAHNC) treated with docetaxel/cisplatin/5-fluorouracil (TPF) followed by cisplatin-containing chemoradiotherapy (CRT).. <i>Journal of Clinical Oncology</i> , 2014, 32, 6053-6053.	1.6	0
394	Sensitivity and specificity of an oral uracil-loading test dose for screening for DPD deficiency.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11101-11101.	1.6	0
395	Variation in the ESR-1 gene as a prognostic marker in early breast cancer survival.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11074-11074.	1.6	0
396	Osteosarcoma of the head and neck (OHN): A multicenter case series of 79 adult patients in the Netherlands.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10542-10542.	1.6	0

#	ARTICLE	IF	CITATIONS
397	A multidisciplinary approach to giant cell tumors of tendon sheath and synovium – A critical appraisal of literature and treatment proposal. <i>Journal of Surgical Oncology</i> , 2013, 107, 433-445.	1.7	60
398	Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells. <i>British Journal of Cancer</i> , 2013, 109, 1214-1222.	6.4	60
399	Experiences with the FACT-EGFRI-18 instrument in EGFRI-associated mucocutaneous adverse events. <i>Supportive Care in Cancer</i> , 2013, 21, 1919-1926.	2.2	17
400	Cardiac glycosides in cancer therapy: from preclinical investigations towards clinical trials. <i>Investigational New Drugs</i> , 2013, 31, 1087-1094.	2.6	133
401	The use of the ¹³ C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 593-601.	2.3	21
402	Breath Tests to Phenotype Drug Disposition in Oncology. <i>Clinical Pharmacokinetics</i> , 2013, 52, 919-926.	3.5	5
403	Concordance of genotype for polymorphisms in DNA isolated from peripheral blood and colorectal cancer tumor samples. <i>Pharmacogenomics</i> , 2013, 14, 2005-2012.	1.3	26
404	Update on Targets and Novel Treatment Options for High-Grade Osteosarcoma and Chondrosarcoma. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 1021-1048.	2.2	65
405	Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) Formulation and Paclitaxel in Polyethoxylated Castor Oil: A Randomized, Two-Period Crossover Study in Patients With Advanced Cancer. <i>Clinical Therapeutics</i> , 2013, 35, 1946-1954.	2.5	81
406	Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib. <i>European Journal of Surgical Oncology</i> , 2013, 39, 150-155.	1.0	58
407	CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 363-373.	2.5	43
408	A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013, 937, 33-43.	2.3	71
409	Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2013, 169, 51-58.	3.7	16
410	Osteosarcoma of the hands and feet: a distinct clinico-pathological subgroup. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 462, 109-120.	2.8	24
411	Addition of interferon- α to the p53- α LP vaccine results in increased production of interferon- γ in vaccinated colorectal cancer patients: A phase I/II clinical trial. <i>International Journal of Cancer</i> , 2013, 132, 1581-1591.	5.1	50
412	Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer: Results of a Compassionate Use Program in The Netherlands. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 238-250.e1.	1.9	26
413	Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2013, 381, 295-302.	13.7	1,144
414	Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis. <i>European Journal of Cancer</i> , 2013, 49, 1027-1031.	2.8	69

#	ARTICLE	IF	CITATIONS
415	Radium-223 Chloride: Extending Life in Prostate Cancer Patients by Treating Bone Metastases. <i>Clinical Cancer Research</i> , 2013, 19, 5822-5827.	7.0	37
416	An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. <i>European Journal of Cancer</i> , 2013, 49, 3219-3228.	2.8	75
417	Translation and linguistic validation of the FACT-EGFRI-18 quality of life instrument from English into Dutch. <i>European Journal of Oncology Nursing</i> , 2013, 17, 802-807.	2.1	4
418	Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 635-661.	4.1	9
419	Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial. <i>Journal of Medical Economics</i> , 2013, 16, 1106-1119.	2.1	13
420	Osteosarcoma: Evolution of Treatment Paradigms. <i>Sarcoma</i> , 2013, 2013, 1-7.	1.3	76
421	Mammalian target of rapamycin inhibitor-associated stomatitis. <i>Future Oncology</i> , 2013, 9, 1883-1892.	2.4	68
422	Tales of How Great Drugs Were Brought Down by a Flawed Rationale Letter. <i>Clinical Cancer Research</i> , 2013, 19, 1303-1303.	7.0	6
423	Osteosarcoma: Lessons Learned and Future Avenues. <i>Sarcoma</i> , 2013, 2013, 1-2.	1.3	4
424	Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency. <i>Pharmacogenomics Journal</i> , 2013, 13, 389-395.	2.0	75
425	Benefits and Adverse Events in Younger Versus Older Patients Receiving Neoadjuvant Chemotherapy for Osteosarcoma: Findings From a Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2013, 31, 2303-2312.	1.6	161
426	MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 208-218.	1.5	17
427	Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes. <i>Journal of Clinical Oncology</i> , 2013, 31, 10503-10503.	1.6	26
428	An open-label international multicentric phase II study of nilotinib in progressive pigmented villo-nodular synovitis (PVNS) not amenable to a conservative surgical treatment. <i>Journal of Clinical Oncology</i> , 2013, 31, 10516-10516.	1.6	8
429	CYP3A4 phenotyping with midazolam to predict sunitinib exposure. <i>Journal of Clinical Oncology</i> , 2013, 31, 2592-2592.	1.6	1
430	Induction chemotherapy (IC) with docetaxel/cisplatin/5-fluorouracil (TPF) followed by cisplatin-containing concomitant chemoradiotherapy (CRT) in fit patients with locally advanced head and neck cancer (LAHNC): The CONDOR study A study of the Dutch Head and Neck Society. <i>Journal of Clinical Oncology</i> , 2013, 31, 6057-6057.	1.6	3
431	Genetic variation in CYP19A1 and occurrence of adverse events in exemestane treatment with early breast cancer patients in the Dutch TEAM trial. <i>Journal of Clinical Oncology</i> , 2013, 31, e22152-e22152.	1.6	1
432	MAP plus maintenance pegylated interferon α -2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 randomization. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA10504-LBA10504.	1.6	14

#	ARTICLE	IF	CITATIONS
433	Pharmacokinetics (PK) of panitumumab in a single patient with metastatic colorectal cancer (mCRC) and liver dysfunction.. Journal of Clinical Oncology, 2013, 31, 594-594.	1.6	0
434	Simultaneous assessment of targeted anticancer therapy-associated mucocutaneous adverse events.. Journal of Clinical Oncology, 2013, 31, e20669-e20669.	1.6	0
435	The influence of gastrointestinal resection on sunitinib exposure in GIST patients.. Journal of Clinical Oncology, 2013, 31, 10547-10547.	1.6	0
436	Safety and efficacy of the addition of simvastatin to panitumumab in <i>KRAS</i> mutant metastatic colorectal cancer patients.. Journal of Clinical Oncology, 2013, 31, e14558-e14558.	1.6	0
437	MAP plus maintenance pegylated interferon α -2b (MAP-IFN) versus MAP alone in patients (pts) with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 good response randomization.. Journal of Clinical Oncology, 2013, 31, LBA10504-LBA10504.	1.6	4
438	Results from a phase III trial (GRID) evaluating regorafenib (REG) in metastatic gastrointestinal stromal tumour (GIST): Subgroup analysis of outcomes based on pretreatment characteristics.. Journal of Clinical Oncology, 2013, 31, 10551-10551.	1.6	1
439	Effect of PK-guided tamoxifen dose escalation on endoxifen serum concentrations in CYP2D6 intermediate and poor metabolizers.. Journal of Clinical Oncology, 2013, 31, 595-595.	1.6	0
440	Phase II multicenter clinical trial of isolated lung perfusion (ILuP) with melphalan (MN) in patients (pts) with resectable lung metastases (LM).. Journal of Clinical Oncology, 2013, 31, 7534-7534.	1.6	0
441	CYP2D6 genotype related to tamoxifen efficacy: An analysis with exclusion of potential false CYP2D6 genotype assignment caused by loss of heterozygosity in tumor tissue.. Journal of Clinical Oncology, 2013, 31, 597-597.	1.6	0
442	Association analysis of polymorphisms in genes related to sunitinib pharmacokinetics.. Journal of Clinical Oncology, 2013, 31, 4580-4580.	1.6	0
443	Safety and efficacy of the addition of simvastatin to cetuximab in <i>KRAS</i> mutant metastatic colorectal cancer patients.. Journal of Clinical Oncology, 2013, 31, e14586-e14586.	1.6	0
444	Inpatient Cetuximab Dose Escalation in Metastatic Colorectal Cancer According to the Grade of Early Skin Reactions: The Randomized EVEREST Study. Journal of Clinical Oncology, 2012, 30, 2861-2868.	1.6	117
445	Quality of Life and Utility in Patients with Metastatic Soft Tissue and Bone Sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) Study. Sarcoma, 2012, 2012, 1-11.	1.3	50
446	Oral Adverse Events Associated with Tyrosine Kinase and Mammalian Target of Rapamycin Inhibitors in Renal Cell Carcinoma: A Structured Literature Review. Oncologist, 2012, 17, 135-144.	3.7	88
447	Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Annals of Oncology, 2012, 23, 1680-1687.	1.2	120
448	Anti-EGFR Antibody Cetuximab Enhances the Cytolytic Activity of Natural Killer Cells toward Osteosarcoma. Clinical Cancer Research, 2012, 18, 432-441.	7.0	97
449	Combination Chemotherapy in Advanced Adrenocortical Carcinoma. New England Journal of Medicine, 2012, 366, 2189-2197.	27.0	692
450	Adjuvant therapy in primary GIST: state-of-the-art. Annals of Oncology, 2012, 23, 2776-2781.	1.2	67

#	ARTICLE	IF	CITATIONS
451	Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials. <i>Annals of Oncology</i> , 2012, 23, 1607-1616.	1.2	166
452	Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients. <i>Annals of Oncology</i> , 2012, 23, 3091-3097.	1.2	10
453	Differences in 5-hydroxytryptamine-3B haplotype frequencies between Asians and Caucasians. <i>International Journal of Biological Markers</i> , 2012, 27, 34-38.	1.8	3
454	Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet</i> , The, 2012, 379, 1879-1886.	13.7	1,752
455	Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2012, 23, vii131-vii138.	1.2	263
456	Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance. <i>Annals of Oncology</i> , 2012, 23, 1617-1626.	1.2	101
457	New treatment modalities in advanced thyroid cancer. <i>Annals of Oncology</i> , 2012, 23, 10-18.	1.2	84
458	Recommendations on management of EGFR inhibitor-induced skin toxicity: A systematic review. <i>Cancer Treatment Reviews</i> , 2012, 38, 505-514.	7.7	53
459	Polymorphisms in Endothelial Nitric Oxide Synthase (eNOS) and Vascular Endothelial Growth Factor (VEGF) Predict Sunitinib-Induced Hypertension. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 503-10.	4.7	74
460	Phenotyping drug disposition in oncology. <i>Cancer Treatment Reviews</i> , 2012, 38, 715-725.	7.7	8
461	Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup. <i>European Journal of Cancer</i> , 2012, 48, 703-712.	2.8	42
462	New Systemic Therapy Options for Advanced Sarcomas. <i>Current Treatment Options in Oncology</i> , 2012, 13, 306-317.	3.0	17
463	Clinical Benefit with Regorafenib Across Subgroups and Post-Progression in Patients with Advanced Gastrointestinal Stromal Tumor (GIST) After Progression on Imatinib (IM) and Sunitinib (SU): Phase 3 Grid Trial Update. <i>Annals of Oncology</i> , 2012, 23, ix478-ix479.	1.2	3
464	Results of a Randomised Phase III Trial (EORTC 62012) of Single Agent Doxorubicin Versus Doxorubicin Plus Ifosfamide as First Line Chemotherapy for Patients with Advanced or Metastatic Soft Tissue Sarcoma: A Survival Study by the Eortc Soft Tissue and Bone Sarcoma Group. <i>Annals of Oncology</i> , 2012, 23, ix28.	1.2	15
465	The Intra-Tumor Stroma Microenvironment in Therapy Management for Colon Cancer Patients. <i>Annals of Oncology</i> , 2012, 23, ix184.	1.2	0
466	Systemic and local human papillomavirus 16-specific T-cell immunity in patients with head and neck cancer. <i>International Journal of Cancer</i> , 2012, 131, E74-85.	5.1	90
467	The fate of camptothecin glycoconjugate: report of a clinical hold during a phase II study of BAY 56-3722 (formerly BAY 38-3441), in patients with recurrent or metastatic colorectal cancer resistant/refractory to irinotecan. <i>Investigational New Drugs</i> , 2012, 30, 1208-1210.	2.6	6
468	Intact interferon signaling in peripheral blood leukocytes of high-grade osteosarcoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 941-947.	4.2	18

#	ARTICLE	IF	CITATIONS
469	Liposomal drug formulations in cancer therapy: 15 years along the road. <i>Drug Discovery Today</i> , 2012, 17, 160-166.	6.4	220
470	Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. <i>Cancer</i> , 2012, 118, 1649-1655.	4.1	222
471	An open-label international multicentric phase II study of nilotinib in progressive pigmented villo-nodular synovitis (PVNS) not amenable to a conservative surgical treatment.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10006-10006.	1.6	3
472	PALETTE: Final overall survival (OS) data and predictive factors for OS of EORTC 62072/GSK VEG110727, a randomized double-blind phase III trial of pazopanib versus placebo in advanced soft tissue sarcoma (STS) patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10009-10009.	1.6	4
473	Association of the genetic variants in the nucleotide excision repair genes XPA and XPC with cisplatin-induced hearing loss in patients with osteosarcoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10077-10077.	1.6	1
474	EURAMOS-1 study: Recruitment, characteristics, and initial treatment of more than 2,000 patients (pts) with high-grade osteosarcoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10081-10081.	1.6	3
475	Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA10008-LBA10008.	1.6	2
476	Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA10008-LBA10008.	1.6	11
477	Genetic variation in CYP19A1 and response to exemestane: Survival in early breast cancer in the Dutch TEAM trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10518-10518.	1.6	0
478	Common polymorphisms in the estrogen receptor-1 may determine risk of hot flashes in early breast cancer patients using tamoxifen.. <i>Journal of Clinical Oncology</i> , 2012, 30, 526-526.	1.6	0
479	Global differences in chemotherapeutic regimens of soft tissue sarcoma (STS): Results of PALETTE, an EORTC 62072/GSK VEG110727 global network phase III trial of pazopanib versus placebo.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10067-10067.	1.6	0
480	Health care utilization (HCU) by breast cancer (BC) and non-Hodgkin lymphoma (NHL) patients (pts) with chemotherapy (CT) induced febrile neutropenia (FN) in the Netherlands.. <i>Journal of Clinical Oncology</i> , 2012, 30, e16526-e16526.	1.6	0
481	Tyrosine kinase inhibitors in differentiated thyroid carcinoma: a review of the clinical evidence. <i>Clinical Investigation</i> , 2011, 1, 241-253.	0.0	3
482	Survival after recurrent osteosarcoma: Data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials. <i>European Journal of Cancer</i> , 2011, 47, 895-902.	2.8	116
483	Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?. <i>European Journal of Cancer</i> , 2011, 47, 2431-2445.	2.8	386
484	In Vitro Schedule-Dependent Interaction Between Melphalan and Oxaliplatin in Human Colorectal Cancer Cell Lines. <i>Journal of Surgical Research</i> , 2011, 167, 273-278.	1.6	23
485	Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients. <i>British Journal of Cancer</i> , 2011, 104, 37-42.	6.4	77
486	Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors. <i>Investigational New Drugs</i> , 2011, 29, 137-143.	2.6	17

#	ARTICLE	IF	CITATIONS
487	Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib. <i>Investigational New Drugs</i> , 2011, 29, 953-962.	2.6	16
488	Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 575-586.	4.2	76
489	Marginal increase of sunitinib exposure by grapefruit juice. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 695-703.	2.3	45
490	Expression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen signaling both in vitro and in vivo. <i>Clinical Sarcoma Research</i> , 2011, 1, 5.	2.3	29
491	Workshop Report on the European Bone Sarcoma Networking Meeting: Integration of Clinical Trials with Tumor Biology. <i>Journal of Adolescent and Young Adult Oncology</i> , 2011, 1, 118-123.	1.3	2
492	Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer. <i>Annals of Oncology</i> , 2011, 22, 1147-1153.	1.2	39
493	Concordance of Predictive Markers for EGFR Inhibitors in Primary Tumors and Metastases in Colorectal Cancer: A Review. <i>Oncologist</i> , 2011, 16, 1239-1249.	3.7	85
494	Mitotane has a strong and a durable inducing effect on CYP3A4 activity. <i>European Journal of Endocrinology</i> , 2011, 164, 621-626.	3.7	99
495	SNPs and Haplotypes in <i>DPYD</i> and Outcome of Capecitabine Letter. <i>Clinical Cancer Research</i> , 2011, 17, 5833-5834.	7.0	5
496	Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib. <i>Clinical Cancer Research</i> , 2011, 17, 620-629.	7.0	150
497	Translation and Validation of EORTC QLQ-C30 into Indonesian Version for Cancer Patients in Indonesia. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 519-529.	1.3	45
498	Association of ABCB1, 5-HT3B Receptor and CYP2D6 Genetic Polymorphisms with Ondansetron and Metoclopramide Antiemetic Response in Indonesian Cancer Patients Treated with Highly Emetogenic Chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 1168-1176.	1.3	31
499	Activation of Tumor-Promoting Type 2 Macrophages by EGFR-Targeting Antibody Cetuximab. <i>Clinical Cancer Research</i> , 2011, 17, 5668-5673.	7.0	91
500	First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC Soft Tissue and Bone Sarcoma Group study. <i>Annals of Oncology</i> , 2011, 22, 207-214.	1.2	163
501	Association between endoxifen serum concentration and predicted CYP2D6 phenotype in a prospective cohort of patients with early-stage breast cancer.. <i>Journal of Clinical Oncology</i> , 2011, 29, 562-562.	1.6	5
502	Effects of Hepatic Function on the Pharmacokinetics and Safety of Panobinostat in Patients with Advanced Cancer: A Phase I Study. <i>Blood</i> , 2011, 118, 5007-5007.	1.4	0
503	Prognostic factors in pulmonary metastasized high-grade osteosarcoma. <i>Pediatric Blood and Cancer</i> , 2010, 54, 216-221.	1.5	69
504	Pharmacogenetics in Oncology: A Promising Field. <i>Current Pharmaceutical Design</i> , 2010, 16, 155-163.	1.9	17

#	ARTICLE	IF	CITATIONS
505	RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. <i>European Radiology</i> , 2010, 20, 1456-1467.	4.5	168
506	Therapeutic modulation of k-ras signaling in colorectal cancer. <i>Drug Discovery Today</i> , 2010, 15, 502-516.	6.4	38
507	Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors. <i>International Journal of Cancer</i> , 2010, 127, 899-909.	5.1	92
508	Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies. <i>British Journal of Cancer</i> , 2010, 102, 1699-1706.	6.4	16
509	Regarding: "Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array". <i>British Journal of Cancer</i> , 2010, 102, 1791-1792.	6.4	0
510	Myelosuppression by sunitinib is flt-3 genotype dependent. <i>British Journal of Cancer</i> , 2010, 103, 757-758.	6.4	19
511	Reply to R. Ferraldeschi et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e586-e586.	1.6	0
512	Management of isolated nonresectable liver metastases in colorectal cancer patients: a case-control study of isolated hepatic perfusion with melphalan versus systemic chemotherapy. <i>Annals of Oncology</i> , 2010, 21, 1662-1667.	1.2	22
513	Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010, 21, v204-v213.	1.2	264
514	Imatinib Mesylate in Advanced Dermatofibrosarcoma Protuberans: Pooled Analysis of Two Phase II Clinical Trials. <i>Journal of Clinical Oncology</i> , 2010, 28, 1772-1779.	1.6	351
515	Reversibility of capillary density after discontinuation of bevacizumab treatment. <i>Annals of Oncology</i> , 2010, 21, 1100-1105.	1.2	44
516	Pharmacogenetics of tomorrow: the 1 + 1 = 3 principle. <i>Pharmacogenomics</i> , 2010, 11, 1011-1017.	1.3	13
517	Sorafenib-Induced Hypothyroidism Is Associated with Increased Type 3 Deiodination. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 3758-3762.	3.6	100
518	Effect of Concomitant CYP2D6 Inhibitor Use and Tamoxifen Adherence on Breast Cancer Recurrence in Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 2423-2429.	1.6	150
519	Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2010, 46, 1829-1834.	2.8	75
520	Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation. <i>European Journal of Cancer</i> , 2010, 46, 3016-3021.	2.8	74
521	Pharmacogenetics of small-molecule tyrosine kinase inhibitors: Optimizing the magic bullet. <i>Current Opinion in Molecular Therapeutics</i> , 2010, 12, 654-61.	2.8	6
522	Gastrointestinal Stromal Tumor in Pregnancy: A Case Report. <i>Case Reports in Medicine</i> , 2009, 2009, 1-4.	0.7	14

#	ARTICLE	IF	CITATIONS
523	Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity. Journal of Clinical Oncology, 2009, 27, 4406-4412.	1.6	177
524	Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array. British Journal of Cancer, 2009, 101, 357-362.	6.4	34
525	Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. European Journal of Endocrinology, 2009, 161, 923-931.	3.7	223
526	Phase I Pharmacokinetic and Pharmacodynamic Study of the Aurora Kinase Inhibitor Danusertib in Patients With Advanced or Metastatic Solid Tumors. Journal of Clinical Oncology, 2009, 27, 5094-5101.	1.6	100
527	Diflomotecan, a promising homocamptothecin for cancer therapy. Expert Opinion on Investigational Drugs, 2009, 18, 69-75.	4.1	26
528	Phase I Dose Escalation Study of Telatinib, a Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor 2 and 3, Platelet-Derived Growth Factor Receptor β_2 , and c-Kit, in Patients With Advanced or Metastatic Solid Tumors. Journal of Clinical Oncology, 2009, 27, 4169-4176.	1.6	42
529	Clinical Implications of <i>CYP2D6</i> Genotyping in Tamoxifen Treatment for Breast Cancer. Clinical Cancer Research, 2009, 15, 15-21.	7.0	74
530	Pharmacogenetics in chemotherapy of colorectal cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2009, 23, 257-273.	2.4	11
531	Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients. Cancer Chemotherapy and Pharmacology, 2009, 63, 1049-1063.	2.3	43
532	Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients. Cancer Chemotherapy and Pharmacology, 2009, 63, 1035-1048.	2.3	26
533	Extra-abdominal subcutaneous metastasis of a gastrointestinal stromal tumor: report of a case and a review of the literature. Journal of Cutaneous Pathology, 2009, 36, 565-569.	1.3	19
534	Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumorigenic pathways. British Journal of Cancer, 2009, 101, 1909-1918.	6.4	67
535	Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. European Journal of Cancer, 2009, 45, 572-578.	2.8	52
536	Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. European Journal of Cancer, 2009, 45, 2293-2297.	2.8	136
537	Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treatment Reviews, 2009, 35, 692-706.	7.7	437
538	Concomitant CYP2D6 inhibitor use and tamoxifen adherence in early-stage breast cancer: A pharmacoepidemiologic study. Journal of Clinical Oncology, 2009, 27, CRA509-CRA509.	1.6	3
539	Phase I safety and pharmacokinetic (PK) study of sunitinib (S) in combination with ifosfamide (I) in patients (pts) with advanced solid tumors (STs). Journal of Clinical Oncology, 2009, 27, e13520-e13520.	1.6	1
540	Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. Journal of Clinical Oncology, 2009, 27, 5006-5006.	1.6	0

#	ARTICLE	IF	CITATIONS
541	Bevacizumab-related hypertension: Search for underlying mechanisms. <i>Journal of Clinical Oncology</i> , 2009, 27, e14520-e14520.	1.6	1
542	Concomitant CYP2D6 inhibitor use and tamoxifen adherence in early-stage breast cancer: A pharmacoepidemiological study. <i>Journal of Clinical Oncology</i> , 2009, 27, CRA509-CRA509.	1.6	6
543	Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008, 874, 84-88.	2.3	60
544	Isolated Hepatic Perfusion with 200Âmg Melphalan for Advanced Noncolorectal Liver Metastases. <i>Annals of Surgical Oncology</i> , 2008, 15, 1891-8.	1.5	43
545	UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. <i>British Journal of Cancer</i> , 2008, 99, 275-282.	6.4	72
546	GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group. <i>British Journal of Cancer</i> , 2008, 99, 1316-1321.	6.4	26
547	Population Pharmacokinetic Model for Docetaxel in Patients with Varying Degrees of Liver Function: Incorporating Cytochrome P450 3A Activity Measurements. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 84, 111-118.	4.7	45
548	NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. <i>Molecular Immunology</i> , 2008, 45, 3917-3925.	2.2	108
549	Clinical and pharmacogenetic factors associated with irinotecan toxicity. <i>Cancer Treatment Reviews</i> , 2008, 34, 656-669.	7.7	82
550	Extremely long survival in six patients despite recurrent and metastatic adrenal carcinoma.. <i>European Journal of Endocrinology</i> , 2008, 158, 911-919.	3.7	34
551	Hypertension and Rarefaction during Treatment with Telatinib, a Small Molecule Angiogenesis Inhibitor. <i>Clinical Cancer Research</i> , 2008, 14, 3470-3476.	7.0	177
552	Effect of Cigarette Smoking on Imatinib in Patients in the Soft Tissue and Bone Sarcoma Group of the EORTC. <i>Clinical Cancer Research</i> , 2008, 14, 8308-8313.	7.0	20
553	False-Positive Serum Human Chorionic Gonadotropin (hCG) in a Male Patient with a Malignant Germ Cell Tumor of the Testis: A Case Report and Review of the Literature. <i>Oncologist</i> , 2008, 13, 1149-1154.	3.7	22
554	Isolated hepatic melphalan perfusion of colorectal liver metastases: outcome and prognostic factors in 154 patients. <i>Annals of Oncology</i> , 2008, 19, 1127-1134.	1.2	41
555	The Clinical Approach Towards Chondrosarcoma. <i>Oncologist</i> , 2008, 13, 320-329.	3.7	602
556	Survival after recurrent osteosarcoma: Data from three European Osteosarcoma Intergroup (EOI) randomized controlled. <i>Journal of Clinical Oncology</i> , 2008, 26, 10505-10505.	1.6	1
557	Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib. <i>Clinical Cancer Research</i> , 2007, 13, 7394-7400.	7.0	107
558	Translating Pharmacogenomics: Challenges on the Road to the Clinic. <i>PLoS Medicine</i> , 2007, 4, e209.	8.4	174

#	ARTICLE	IF	CITATIONS
559	Cyclopentenyl Cytosine (CPEC): An Overview of its in vitro and in vivo Activity. Current Cancer Drug Targets, 2007, 7, 504-509.	1.6	26
560	Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Annals of Oncology, 2007, 18, 1745-1747.	1.2	118
561	Insights into the role of heritable genetic variation in the pharmacokinetics and pharmacodynamics of anticancer drugs. Expert Opinion on Pharmacotherapy, 2007, 8, 1197-1210.	1.8	17
562	Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. European Journal of Cancer, 2007, 43, 845-851.	2.8	136
563	Hepatic artery infusion of high-dose melphalan at reduced flow during isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: A clinical and pharmacologic evaluation. European Journal of Surgical Oncology, 2007, 33, 874-881.	1.0	26
564	Pharmacogenetics of EGFR and VEGF inhibition. Drug Discovery Today, 2007, 12, 1054-1060.	6.4	46
565	Small Molecule Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: An Update of Recent Developments. Annals of Surgical Oncology, 2007, 14, 942-953.	1.5	128
566	Is rectal administration an alternative route for imatinib?. Cancer Chemotherapy and Pharmacology, 2007, 60, 623-624.	2.3	6
567	Pharmacological Background. , 2007, , 19-28.		0
568	72 POSTER Phase I, safety, pharmacokinetic and biomarker study of telatinib (BAY 57-9352), an oral VEGFR-2 inhibitor, in a continuous schedule in patients with advanced solid tumors. European Journal of Cancer, Supplement, 2006, 4, 26.	2.2	3
569	VEGFR2 blockade in patients with solid tumors: Mechanism of hypertension and effects on vascular function. Vascular Pharmacology, 2006, 45, e42-e43.	2.1	5
570	VEGFR2 blockade in patients with solid tumors: Mechanism of hypertension and effects on vascular function. Journal of Clinical Oncology, 2006, 24, 3037-3037.	1.6	6
571	Phase I, safety, pharmacokinetic and biomarker study of BAY 57-9352, an oral VEGFR-2 inhibitor, in a continuous schedule in patients with advanced solid tumors. Journal of Clinical Oncology, 2006, 24, 3040-3040.	1.6	0
572	Skeletal Retention of Bisphosphonate (Pamidronate) and Its Relation to the Rate of Bone Resorption in Patients With Breast Cancer and Bone Metastases. Journal of Bone and Mineral Research, 2005, 20, 1543-1547.	2.8	43
573	Survival of Patients with Ovarian Cancer due to a Mismatch Repair Defect. Familial Cancer, 2005, 4, 301-305.	1.9	63
574	Association of Paclitaxel Pharmacokinetics with the Development of Peripheral Neuropathy in Patients with Advanced Cancer. Clinical Cancer Research, 2005, 11, 4843-4850.	7.0	113
575	Effect of Milk Thistle (<i>Silybum marianum</i>) on the Pharmacokinetics of Irinotecan. Clinical Cancer Research, 2005, 11, 7800-7806.	7.0	115
576	Effect of ABCG2 genotype on the oral bioavailability of topotecan. Cancer Biology and Therapy, 2005, 4, 650-653.	3.4	161

#	ARTICLE	IF	CITATIONS
577	Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. <i>Cancer Treatment Reviews</i> , 2005, 31, 90-105.	7.7	161
578	Pharmacokinetics (PK) of free and total paclitaxel after equal doses of paclitaxel injectable emulsion and paclitaxel injection. <i>Journal of Clinical Oncology</i> , 2005, 23, 2045-2045.	1.6	3
579	Factors Affecting Cytochrome P-450 3A Activity in Cancer Patients. <i>Clinical Cancer Research</i> , 2004, 10, 8341-8350.	7.0	119
580	Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. <i>British Journal of Cancer</i> , 2004, 90, 304-305.	6.4	124
581	Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. <i>International Journal of Cancer</i> , 2004, 109, 468-471.	5.1	105
582	Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype*1. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 38-44.	4.7	222
583	Evaluation of CYP3A activity as a predictive covariate for docetaxel clearance. <i>Journal of Clinical Oncology</i> , 2004, 22, 2006-2006.	1.6	2
584	Effect of ABCG2 genotype and mRNA expression on the bioavailability of topotecan. <i>Journal of Clinical Oncology</i> , 2004, 22, 2015-2015.	1.6	10
585	Whole body retention in relation to rate of bone resorption after intravenous bisphosphonate (pamidronate) in patients with breast cancer and bone metastases. <i>Journal of Clinical Oncology</i> , 2004, 22, 881-881.	1.6	1
586	Influence of the cisplatin hydration schedule on topotecan pharmacokinetics. <i>European Journal of Cancer</i> , 2003, 39, 1542-1546.	2.8	3
587	Red blood cells: a neglected compartment in topotecan pharmacokinetic analysis. <i>Anti-Cancer Drugs</i> , 2003, 14, 227-232.	1.4	13
588	Distribution of paclitaxel in plasma and cerebrospinal fluid. <i>Anti-Cancer Drugs</i> , 2003, 14, 365-368.	1.4	8
589	Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors. <i>Clinical Cancer Research</i> , 2003, 9, 4101-7.	7.0	35
590	Comparative Pharmacokinetics of Unbound Paclitaxel During 1- and 3-Hour Infusions. <i>Journal of Clinical Oncology</i> , 2002, 20, 574-581.	1.6	48
591	Modulation of cisplatin pharmacodynamics by Cremophor EL. <i>European Journal of Cancer</i> , 2002, 38, 205-213.	2.8	13
592	Comparative Pharmacokinetics of Unbound Paclitaxel During 1- and 3-Hour Infusions. <i>Journal of Clinical Oncology</i> , 2002, 20, 574-581.	1.6	73
593	Determination of topotecan in human whole blood and unwashed erythrocytes by high-performance liquid chromatography. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002, 766, 99-105.	2.3	25
594	Influence of Cremophor EL on the bioavailability of intraperitoneal paclitaxel. <i>Clinical Cancer Research</i> , 2002, 8, 1237-41.	7.0	69

#	ARTICLE	IF	CITATIONS
595	Cremophor EL. European Journal of Cancer, 2001, 37, 1590-1598.	2.8	1,458
596	Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer. British Journal of Cancer, 2001, 85, 1124-1129.	6.4	14
597	Phase I Pharmacologic Study of Oral Topotecan and Intravenous Cisplatin: Sequence-Dependent Hematologic Side Effects. Journal of Clinical Oncology, 2000, 18, 2104-2115.	1.6	62
598	Topotecan lacks third space sequestration. Clinical Cancer Research, 2000, 6, 1288-92.	7.0	7
599	Inter- and inpatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens. Clinical Cancer Research, 2000, 6, 2685-9.	7.0	37
600	Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Research, 1999, 59, 1454-7.	0.9	252
601	Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function. Drug Metabolism and Disposition, 1999, 27, 1300-5.	3.3	16
602	Outcome of Surgical Treatment for Patients with Diffuse-Type Tenosynovial Giant Cell Tumours. SSRN Electronic Journal, 0, , .	0.4	4